Corindus Vascular Robotics teams up to improve atherosclerosis procedure

Atherosclerosis in the distal right coronary artery--Courtesy of Michael Bonert CC BY-SA 3.0

Corindus Vascular Robotics and Acist Medical Systems are joining forces to improve the workflow of percutaneous coronary intervention for atherosclerosis at a Minnesota hospital. Corindus will offer its robotic-assisted system, while Acist will contribute systems to simplify contrast injections and measure fractional flow reserve (FFR) for the procedure.

Industry players, including Medtronic ($MDT) and Johnson & Johnsom ($JNJ), have been racing to get in on robotic surgery, which has historically been dominated by Intuitive Surgical ($ISRG). And there has been a recent surge of interest in minimally invasive robotic surgery as the concept gains traction as a viable alternative to laparoscopic surgery.

PCI is a nonsurgical procedure that uses a catheter to place and deploy a stent in coronary vessels that have narrowed. After the patient is sedated, the catheter is inserted in the arm or the groin. Once it reaches the heart, a contrast dye is released to show where the blood vessel is narrowed.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Corindus, a micro-cap worth about $150 million, markets the CorPath system, the first FDA-cleared robotic-assisted system for PCI. It is designed to improve precision in stent placement during PCI procedures. Additionally, it makes the procedure easier for the cardiologist: instead of wearing heavy lead protective gear, an interventional cardiologist operates the device from a radiation-shielded workstation. Acist’s CVi, a “smart contrast injection system,” simplifies contrast injection while improving safety, efficiency, control and image quality, while its RXi FFR system provides accurate and reliable fractional flow reserve readings.

“This collaboration is the first step towards realizing this vision by providing innovative solutions to optimize workflow, improve safety, and eventually enhance patient care,” said Corindus CEO Mark Toland, in the statement.

Corindus and Acist will initially work with Fairview Southdale Hospital in Edina, MN to improve PCI workflow, but the duo has a bigger goal in mind. “We look forward to furthering the reach of Corindus and ACIST so that more clinicians and patients can benefit from these advanced technologies,” said Acist COO Tom Morizio, in the statement.

- here's the statement

Related Articles:
St. Jude launches study comparing its imaging tech to other modalities during stenting procedures
Vascular robotics player Corindus files to list on NYSE, raise $46M

Suggested Articles

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

What a difference a day makes in biotech.

As public fascination with at-home DNA tests begins to wane, 23andMe announced that it will lay off about 100 of its staff, according to CNBC.